TFB Advisors LLC Boosts Stake in Pfizer Inc. (NYSE:PFE)

TFB Advisors LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,807 shares of the biopharmaceutical company’s stock after purchasing an additional 655 shares during the period. TFB Advisors LLC’s holdings in Pfizer were worth $419,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Exchange Traded Concepts LLC increased its position in shares of Pfizer by 117.0% during the third quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock worth $2,002,000 after acquiring an additional 37,293 shares during the period. CX Institutional increased its holdings in Pfizer by 80.1% during the 3rd quarter. CX Institutional now owns 46,207 shares of the biopharmaceutical company’s stock worth $1,337,000 after purchasing an additional 20,552 shares during the period. Creative Planning raised its position in Pfizer by 17.1% in the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after purchasing an additional 266,167 shares in the last quarter. Occidental Asset Management LLC grew its position in shares of Pfizer by 4.1% during the third quarter. Occidental Asset Management LLC now owns 13,774 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 544 shares in the last quarter. Finally, NBC Securities Inc. increased its stake in shares of Pfizer by 0.7% during the third quarter. NBC Securities Inc. now owns 61,834 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 407 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 0.3 %

Shares of Pfizer stock opened at $25.46 on Thursday. The company’s fifty day moving average is $26.28 and its two-hundred day moving average is $27.65. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $144.28 billion, a P/E ratio of 18.06, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.